Bifidobacterium animalis in combination with human origin of Lactobacillus plantarum ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance

Salehipour, Zohre; Haghmorad, Dariush; Sankian, Mojtaba; Rastin, Maryam; Nosratabadi, Reza; Dallal, Mohammad Mehdi Soltan; Tabasi, Nafiseh; Khazaee, Mahdieh; Nasiraii, Leila Roozbeh; Mahmoudi, Mahmoud

doi:10.1016/j.biopha.2017.08.117

Cited by 120 publications

(103 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, we show that oral treatment with Lactibiane iki improves the clinical outcome of EAE mice in a dose-dependent manner as a therapeutic approach. The clinical improvement was related to decreased CNS demyelination and inflammation, as corroborated by many previous studies of probiotic treatment [7][8][9][10][11][12][13]. Lactibiane iki treatment also decreases the expression of the Th17-defining transcription factor Rorγt in the spinal cord, revealing a reduction in this pro-inflammatory cell population previously connected to both EAE [45] and MS [46] pathogenesis in the CNS.…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

Calvo-Barreiro

Eixarch

Ponce-Alonso

et al. 2020

Cells

View full text Add to dashboard Cite

Previous studies in experimental autoimmune encephalomyelitis (EAE) models have shown that some probiotic bacteria beneficially impact the development of this experimental disease. Here, we tested the therapeutic effect of two commercial multispecies probiotics-Lactibiane iki and Vivomixx-on the clinical outcome of established EAE. Lactibiane iki improves EAE clinical outcome in a dose-dependent manner and decreases central nervous system (CNS) demyelination and inflammation. This clinical improvement is related to the inhibition of pro-inflammatory and the stimulation of immunoregulatory mechanisms in the periphery. Moreover, both probiotics modulate the number and phenotype of dendritic cells (DCs). Specifically, Lactibiane iki promotes an immature, tolerogenic phenotype of DCs that can directly induce immune tolerance in the periphery, while Vivomixx decreases the percentage of DCs expressing co-stimulatory molecules. Finally, gut microbiome analysis reveals an altered microbiome composition related to clinical condition and disease progression. This is the first preclinical assay that demonstrates that a commercial probiotic performs a beneficial and dose-dependent effect in EAE mice and one of the few that demonstrates a therapeutic effect once the experimental disease is established. Because this probiotic is already available for clinical trials, further studies are being planned to explore its therapeutic potential in multiple sclerosis patients.

show abstract

Section: Discussionsupporting

confidence: 81%

“…However, experimental data support the idea that some bacterial strains, far from being harmful, have a beneficial impact on the outcome of EAE. Thus, the promotion of beneficial microorganisms via probiotics is being developed as an important therapeutic strategy involving the gut microbiota in EAE [7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

Calvo-Barreiro

Eixarch

Ponce-Alonso

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…Furthermore, a recent study reported that supplementation of MS patients with a cocktail of three Lactobacillus species and one Bifidobacterium species was associated with improved Expanded Disability Status Scale (EDSS) score as well as decreased depression and stress . Others studies conducted in the EAE mouse model have demonstrated that administration of a cocktail of Lactobacillus species and/or Bifidobacterium species either before or after EAE induction ameliorate EAE . Hence, these studies suggest that increased in the relative abundance of Lactobacillus and Bifidobacterium taxa following LBS supplementation could be beneficial to MS patients.…”

Section: Resultsmentioning

confidence: 93%

“…36 Others studies conducted in the EAE mouse model have demonstrated that administration of a cocktail of Lactobacillus species and/or Bifidobacterium species either before or after EAE induction ameliorate EAE. 37,38 Hence, these studies suggest that increased in the relative abundance of Lactobacillus and Bifidobacterium taxa following LBS supplementation could be beneficial to MS patients.…”

Section: Administration Of Probiotic Lbs Is Associated With Changes Imentioning

confidence: 88%

A probiotic modulates the microbiome and immunity in multiple sclerosis

Tankou

Regev

Healy

et al. 2018

Annals of Neurology

194

116

View full text Add to dashboard Cite

Objective Effect of a probiotic on the gut microbiome and peripheral immune function in healthy controls and relapsing-remitting multiple sclerosis (RRMS) patients. Methods MS patients (N=9) and controls (N=13) were orally administered a probiotic containing Lactobacillus, Bifidobacterium and Streptococcus twice daily for two months. Blood and stool specimens were collected at baseline, after completion of the 2-month treatment, and 3 months after discontinuation of therapy. Frozen peripheral blood mononuclear cells (PBMCs) were used for immune cell profiling. Stool samples were used for 16S rRNA profiling and metabolomics. Results Probiotic administration increased the abundance of several taxa known to be depleted in MS such as Lactobacillus. We found that probiotic use decreased the abundance of taxa previously associated with dysbiosis in MS including Akkermansia and Blautia. Predictive metagenomic analysis revealed a decrease in the abundance of several KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathways associated with altered gut microbiota function in MS patients such as methane metabolism following probiotic supplementation. At the immune level, probiotic administration induced an anti-inflammatory peripheral immune response characterized by decreased frequency of inflammatory monocytes, decreased mean fluorescence intensity (MFI) of CD80 on classical monocytes as well as decreased HLA-DR MFI on dendritic cells. Probiotic administration was also associated with decreased expression of MS risk allele HLA-DQA1 in controls. Probiotic induced increased in the abundance of Lactobacillus and Bifidobacterium were associated with decreased expression of MS risk allele HLA.DPB1 in controls. Interpretation Our results suggest that probiotic could have a synergistic effect with current MS therapies.

show abstract

“…The preventive treatment suppressed EAE development, while IRT5 administration during EAE only delayed disease onset; probiotic administration increased the percentage of FOXP3 + regulatory T cells and IL‐10 levels in the spinal cord . A recent study discovered that L. plantarum A7 combined with B. animalis PTCC 1631 caused a delay in EAE onset and a reduction of mononuclear infiltration into the CNS and enhanced the CD4 + CD25 + FOXP3 + T cells in the spleen and lymph nodes . Another research group also observed the beneficial effects of the Escherichia coli strain Nissle 1917 when administered to the EAE animal model.…”

Section: Microbiota and Probiotics In Autoimmune Diseasesmentioning

confidence: 98%

Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?

Rinaldi

Consonni

Guidesi³

et al. 2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Gut microorganisms (microbiota) live in symbiosis with the host and influence human nutrition, metabolism, physiology, and immune development and function. The microbiota prevents pathogen infection to the host, and in turn the host provides a niche for survival. The alteration of gut bacteria composition (dysbiosis) could contribute to the development of immune-mediated diseases by influencing the immune system activation and driving the pro- and anti-inflammatory responses in order to promote or counteract immune reactions. Probiotics are nonpathogenic microorganisms able to interact with the gut microbiota and provide health benefits; their use has recently been exploited to dampen immunological response in several experimental models of autoimmune diseases. Here, we focus on the relationships among commensal bacteria, probiotics, and the gut, describing the main interactions occurring with the immune system and recent data supporting the clinical efficacy of probiotic administration in rheumatoid arthritis, multiple sclerosis, and myasthenia gravis (MG) animal models. The encouraging results suggest that selected strains of probiotics should be evaluated in clinical trials as adjuvant therapy to restore the disrupted tolerance in myasthenia gravis.

show abstract

Bifidobacterium animalis in combination with human origin of Lactobacillus plantarum ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance

Cited by 120 publications

References 59 publications

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis

A probiotic modulates the microbiome and immunity in multiple sclerosis

Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?

Contact Info

Product

Resources

About